CGON - CIK 0001991792
The table below shows CG Oncology, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$132.35M | -$78.71M | -$45.68M |
| Capital expenditure | $134.00K | $234.00K | - |
| Investing cash flow | -$245.82M | -$300.76M | -$121.19M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $153.59M | $628.28M | $87.00M |
CG Oncology, Inc. reported operating cash flow of -$132.35M for fiscal year 2025. That is down 68.1% from -$78.71M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.